Previous 10 | Next 10 |
Established diversified pipeline of three clinical-stage gene therapy programs for serious neurological disorders including Parkinson’s disease, GM1 gangliosidosis, and Tay-Sachs SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for Parkinson's disease continues to enroll patients i...
The following slide deck was published by Axovant Gene Therapies Ltd. in conjunction with this Read more ...
Gainers: Stewardship Financial (NASDAQ: SSFN ) +73% . Beyond Meat (NASDAQ: BYND ) +36% . La Jolla Pharmaceutical (NASDAQ: LJPC ) +25% . ReWalk Robotics (NASDAQ: RWLK ) +26% . Neptune Wellness Solutions (NASDAQ: NEPT ) +21% . Zoom Video Communications (NASDAQ: ZM ) +21% . Horizo...
Thinly traded micro cap Axovant Gene Therapies (NASDAQ: AXGT ) is up 8% premarket on modestly higher volume in reaction to encouraging six-month follow-up data from the first dose cohort in a Phase 2 clinical trial, SUNRISE-PD, evaluating gene therapy AXO-Lenti-PD in Parkinson'...
ContraVir Pharmaceuticals (NASDAQ: CTRV ) +123% on encouraging CRV431 data . More news on: ContraVir Pharmaceuticals, Inc., Stitch Fix, Inc., Ciena Corporation, Stocks on the move, Read more ...
AXO-Lenti-PD was observed to be generally well tolerated at six months, and continued to demonstrate benefits in both patients across multiple measures after a single administration Totality of data across the program at 6 months supports overall favorable product profile Initial three-...
The global market for neurodegeneration treatments is estimated to be 20 billion and will grow 6% annually. The most prevalent neurodegenerations are Alzheimer's disease ((AD)) and Parkinson's disease ((PD)). Nilotinib, a tyrosine kinase inhibitor developed by Novartis (NVS) and approved for l...
BASEL, Switzerland, May 31, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will present at three conferences in June. Annual Roivant Pi...
BASEL, Switzerland, May 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will present at the 2019 RBC Capital Markets Global Healthcare C...
AUBURN, Ala. , May 17, 2019 /PRNewswire/ -- The first clinical trial of a gene therapy treatment created through a research alliance between Auburn University and the University of Massachusetts has been administered in a child at the National Institutes of Health, or NIH, in Be...
News, Short Squeeze, Breakout and More Instantly...
Axovant Gene Therapies Ltd. Company Name:
AXGT Stock Symbol:
NYSE Market:
On-track to report t opline r esults from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to ra...
A pioneering researcher , Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of...
Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 ...